Development of Peptide Fusion Inhibitors Targeting HIV-1 gp41

摘要

HIV-1 membrane fusion plays an important role in the process that HIV-1 entrys cells. As a new treatment options targeting HIV-1 entry process, fusion inhibitors have been proposed. Peptide T20 which derived from viral envelope glycoprotein gp41, is the first and only HIV-1 fusion inhibitor approved by the FDA. Currently, a large number of prospective fusion peptides have emerged. This paper introduced the possible mechanism of fusion inhibitor, reported the current developments and innovative designs of HIV-1 membrane fusion inhibitors.